Evogene After the Warrant Inducement: How Much Time Was Bought, and How Much Dilution Still Sits Above the Stock
The February 2026 warrant deal brought Evogene immediate cash, but probably bought only a few months of time while leaving a visible dilution stack that can reach almost 80% of the March 2026 share base. The story now is not just funding, but the pace at which that overhang can still open up if the stock recovers.
What This Deal Actually Bought
The main article argued that Evogene came out of 2025 more focused, but still trapped by one bottleneck, funding. This follow-up isolates the February 2026 warrant inducement because that is where three threads met at once: immediate liquidity relief, a slower-release issuance mechanism, and a much larger dilution ceiling sitting over the stock.
The short version is simple. Evogene took 3.38 million old warrants with a $3.55 strike, repriced them to $1.00 for immediate cash exercise, and in exchange issued 5.08 million new warrants at a $1.25 strike. That helped liquidity now, but it also created a new overhang that is larger, cheaper, and longer-lived than the one it removed.
The less obvious point is that the dilution did not hit all at once. Evogene had 8.72 million shares outstanding at the end of 2025. By March 15, 2026, that number had risen to 9.89 million. That is an increase of about 1.18 million shares, not 3.38 million. The transaction documents explain why: the holder is capped at 4.99% beneficial ownership, and any portion that would push the holder above that limit is held in abeyance until it can be issued without breaching the cap. In other words, some of the dilution is already in the base, while another layer remains economically committed but still waiting to be released.
That is the core of the continuation thesis. Evogene did not just raise cash. It converted an immediate liquidity problem into a capital-structure problem that can unfold over time instead of in one step. For common shareholders, that means the funding issue is not gone. It has simply changed shape.
The chart above is not a forecast. It is a capital-structure map. The hard layers are the paid shares still waiting in abeyance and the 5.08 million new warrants. The S-8 layer is softer because it depends on grants and exercises over time, but it still sits above existing shareholders. If all visible layers eventually materialize, the share base would reach roughly 17.76 million, a little more than double the year-end 2025 count.
How Much Time It Really Added
From a cash perspective, the transaction gave Evogene oxygen, but not a new year of freedom. The exercise of the old warrants brought in about $3.385 million of gross proceeds. The full filing also shows the immediate cost of that money: a 7% advisory fee plus reimbursement of up to $20,000 of legal expenses. Those two disclosed deductions alone reduce the proceeds to roughly $3.13 million at best, and that is before other transaction expenses that were mentioned but not quantified.
Once translated into Evogene’s 2025 burn profile, the picture sharpens. Net cash used in operating activities was $13.5 million in 2025. On that base, the gross proceeds buy about 3.0 months, and the amount after the identifiable deductions falls to less than 2.8 months. If the analysis is limited to continuing operations, excluding discontinued activity, the burn rate was about $11.4 million, which means roughly 3.6 months on a gross basis and about 3.3 months after the identifiable deductions. That difference matters, which is why this deal should not be read as a funding solution. At most, it is a short bridge.
The point of that chart is that the extra time is real, but limited. Management itself did not anchor the next 12 months on cash alone. Its twelve-month liquidity framework also relies on cash-preservation measures, possible headcount reductions, and the deferral or reprioritization of research and development programs if projected revenues do not arrive on time. That means the February cash is only part of the bridge, not proof that the current business is fully funded on its existing cash profile.
There is another nuance that matters. Note 24 also introduced non-dilutive liquidity sources after year-end: Evogene received about $2.93 million in March 2026 from a Lavie Bio dividend, and Biomica approved a dividend of up to $2.7 million subject to court approval. That improves the broader liquidity picture, but it does not change the core point here. The February warrant transaction bought time, but it did not resolve the capital question on its own.
Where The Remaining Dilution Still Sits
The right way to read this deal is through three distinct layers:
| Layer | Size | Status | What it means in practice |
|---|---|---|---|
| Dilution already inside the base | About 1.18 million shares | Already reflected in the March 15, 2026 share count | This is the visible part that has already hit existing holders |
| Paid shares still held in abeyance | About 2.21 million shares | Already paid for, but delayed by the ownership cap | This is an overhang that can continue to feed into the market |
| New warrants | 5.08 million shares at $1.25 | Contingent dilution, but very large | If the stock recovers, this can also become roughly $6.35 million of gross financing |
| New S-8 registration | 582,407 shares | Not issued yet, but registered for issuance | 83,230 relate to outstanding options and 499,177 are available for future grants |
What matters most is the weight of those layers. The new warrants alone equal roughly 51% of the mid-March 2026 share base. The paid shares still sitting in abeyance add another 22%. The S-8 adds another 5.9%. Together, that is a visible dilution stack of almost 80% above the share base that already exists.
It also matters what the transaction did not do. It did not shut the door on further dilution. The inducement letter blocks new share issuance or new registration filings for 45 days after closing and restricts variable-rate deals for six months, but it explicitly leaves an ATM exception open after 15 days. That is a short tactical pause, not a durable wall.
Even the shelf capacity does not look wide. As of March 19, 2026, the company said that because of the one-third-of-public-float rule, it could raise only about $3.51 million under the shelf over a twelve-month period. That is roughly the same order of magnitude as the warrant inducement itself. So if liquidity pressure reopens before other cash sources mature, Evogene may find itself back in front of the market for a similar-sized financing, potentially from a weaker starting point.
Why Nasdaq Risk Sits On The Exact Same Fault Line
The Nasdaq section is not just legal background. It is part of the economics of this transaction. The company disclosed that its closing price was $0.94 on March 12, 2026, below Nasdaq’s $1.00 minimum bid requirement. It also noted that a January 2025 rule change means that if a company falls below the minimum again after having completed a reverse split in the prior year, it may not be entitled to another compliance period at all.
That connects directly to the new capital structure. The new warrants carry a $1.25 strike. So for that overhang to become something more than dilution risk, the stock first has to clear two thresholds: back above $1.00 to relieve listing pressure, and then toward or above $1.25 to make exercise more economic. As long as the stock is below both levels, the market is likely to focus on future supply, not on future financing potential.
That may be the most important point in this continuation. The deal bought time in the near term, but the next capital leg already sitting in the structure depends first on repairing the stock itself. The listing issue and the dilution issue are not two separate stories. They are the same story.
Conclusion
February 2026 gave Evogene a liquidity bridge, not capital independence. The transaction pulled cash forward, improved immediate flexibility, and spread part of the issuance over time through the abeyance mechanism. But the price was the replacement of 3.38 million old warrants with a new layer of 5.08 million cheaper warrants, alongside a block of already-paid shares waiting to be released and a fresh S-8 registration on top.
If the focus stays only on the cash that came in, the market can read the deal as a quarter or two of breathing room. If the focus shifts to the whole capital structure, the picture is sharper: Evogene bought a relatively short amount of time while leaving behind a dilution mechanism that may reopen precisely when the stock starts to recover. That is why the key question from here is not whether the company managed to raise money. It is whether the time bought in February is enough to reach the next business and liquidity checkpoint without reopening the capital gap for common shareholders.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.